Literature DB >> 2691926

Gammahydroxybutyrate: an endogenous regulator of energy metabolism.

M Mamelak1.   

Abstract

Gammahydroxybutyrate is a naturally occurring metabolite of many mammalian tissues. Although its administration produces a wide range of pharmacological effects, its normal function has never been clearly defined. GHB can induce NREM and REM sleep, anaesthesia, hypothermia, and a trance-like state which has been considered a model for petit mal epilepsy. It markedly increases brain dopamine levels. It has been touted as a central neurotransmitter or neuromodulator, and high affinity brain receptors, as well as central mechanisms for its synthesis, uptake and release have been demonstrated in support of this. But GHB is also found in many peripheral tissues and in some of these in higher concentrations than in the brain. No explanation has been offered for its presence in these tissues. A number of studies indicate that GHB can reduce energy substrate consumption in both brain and peripheral tissues, and that it can protect these tissues from the damaging effects of anoxia or excessive metabolic demand. Indeed there is some evidence to suggest that endogenous GHB levels rise under these circumstances. GHB appears to act through the endogenous opioid system, since in the brain, at least, GHB raises dynorphin levels and its metabolic and pharmacological effects can be blocked by naloxone. These, and other observations detailed in this review, suggest that GHB may function naturally in the induction and maintenance of physiological states, like sleep and hibernation, in which energy utilization is depressed. GHB may also function naturally as an endogenous protective agent when tissue energy supplies are limited.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2691926     DOI: 10.1016/s0149-7634(89)80053-3

Source DB:  PubMed          Journal:  Neurosci Biobehav Rev        ISSN: 0149-7634            Impact factor:   8.989


  29 in total

1.  Another health food hazard--gamma-hydroxybutyrate-induced seizures.

Authors:  B T Adornato; V Tse
Journal:  West J Med       Date:  1992-10

2.  Further evaluation of Vigabatrin therapy in 4-hydroxybutyric aciduria.

Authors:  C Jakobs; T Michael; E Jaeger; J Jaeken; K M Gibson
Journal:  Eur J Pediatr       Date:  1992-06       Impact factor: 3.183

3.  Acute poisoning from gamma-hydroxybutyrate in California.

Authors:  M Y Chin; R A Kreutzer; J E Dyer
Journal:  West J Med       Date:  1992-04

4.  Sodium oxybate: a potential new pharmacological option for the treatment of fibromyalgia syndrome.

Authors:  Todd J Swick
Journal:  Ther Adv Musculoskelet Dis       Date:  2011-08       Impact factor: 5.346

5.  Metabolomic study of polyamines in rat urine following intraperitoneal injection of γ-hydroxybutyric acid.

Authors:  Hyeon-Seong Lee; Chan Seo; Young-A Kim; Meejung Park; Boyeon Choi; Moongi Ji; Sooyeun Lee; Man-Jeong Paik
Journal:  Metabolomics       Date:  2019-04-02       Impact factor: 4.290

6.  Inhibition of rat brain lipid synthesis in vitro by 4-hydroxybutyric acid.

Authors:  A R Silva; C Ruschel; C Helegda; A M Brusque; C M Wannmacher; M Wajner; C S Dustra-Filho
Journal:  Metab Brain Dis       Date:  1999-09       Impact factor: 3.584

Review 7.  Pharmacological Treatment in γ-Hydroxybutyrate (GHB) and γ-Butyrolactone (GBL) Dependence: Detoxification and Relapse Prevention.

Authors:  Rama M Kamal; Martijn S van Noorden; Wim Wannet; Harmen Beurmanjer; Boukje A G Dijkstra; Arnt Schellekens
Journal:  CNS Drugs       Date:  2017-01       Impact factor: 5.749

8.  gamma-aminobutyric acid type B receptors are expressed and functional in mammalian cardiomyocytes.

Authors:  P Lorente; A Lacampagne; Y Pouzeratte; S Richards; B Malitschek; R Kuhn; B Bettler; G Vassort
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

9.  Therapeutic concepts in succinate semialdehyde dehydrogenase (SSADH; ALDH5a1) deficiency (gamma-hydroxybutyric aciduria). Hypotheses evolved from 25 years of patient evaluation, studies in Aldh5a1-/- mice and characterization of gamma-hydroxybutyric acid pharmacology.

Authors:  I Knerr; P L Pearl; T Bottiglieri; O Carter Snead; C Jakobs; K M Gibson
Journal:  J Inherit Metab Dis       Date:  2007-04-24       Impact factor: 4.982

10.  Cardioprotective action of sodium gamma-hydroxybutyrate against isoproterenol induced myocardial damage.

Authors:  A Kolin; A Brezina; M Mamelak; E Pandula
Journal:  Int J Exp Pathol       Date:  1993-06       Impact factor: 1.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.